Terrance McGuire, a director at Invivyd, Inc. (NASDAQ:IVVD), has reported a series of stock sales totaling $164,867, according to a recent SEC filing. The transactions occurred over several days in December, with shares sold at prices ranging from $0.4234 to $0.5436. The sales come as the $61 million market cap company maintains impressive gross profit margins of 92%, though InvestingPro analysis indicates the company is quickly burning through cash.
On December 20, McGuire sold 119,805 shares, followed by 75,776 shares on December 23, 68,161 shares on December 24, and 83,817 shares on December 26. After these transactions, McGuire holds 3,340,520 shares indirectly through Polaris (NYSE:PII) Partners IX, L.P., as noted in the filing. The stock has shown recent volatility, with a 19% gain in the past week despite an 87% decline over the past year.
These sales reflect McGuire’s ongoing management of his investment in Invivyd, a company specializing in biological products. InvestingPro data reveals the company maintains a healthy current ratio of 1.92, though its overall financial health score is rated as weak. Subscribers can access 10+ additional ProTips and comprehensive financial metrics for deeper analysis.
In other recent news, Invivyd, Inc. reported steady growth in its third-quarter financial results, with net product revenue of $9.3 million and an ending cash balance of $107 million. The company also announced the resignation of Sara Cotter from its Board of Directors. Despite regulatory challenges and efficacy concerns for its COVID-19 antibody, pemivibart, Invivyd highlighted an 80% to 90% reduction in symptomatic COVID-19 risk. The company also introduced a new antibody candidate, VYD2311, which began human studies in August 2024. Invivyd is aiming for profitability by June 2025 through a strategic restructuring to enhance commercial outreach, primarily serving the immunocompromised community. Furthermore, the company is in discussions with the FDA regarding the regulatory pathway for VYD2311. Despite concerns about pemivibart’s efficacy against certain SARS-CoV-2 variants, Invivyd remains confident in its clinical data and regulatory pathway for its products. These are the recent developments in the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.